Krebs Biochemicals and Industries Limited
Krebs Biochemicals and Industries Limited (KREBSBIO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
krebsbiochem.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 6 Cr | 5 Cr | 4 Cr | 7 Cr |
| Operating expenses (approx.) | 12 Cr | 8 Cr | 7 Cr | 7 Cr |
| EBITDA | -5 Cr | -2 Cr | -3 Cr | 0.30 Cr |
| OPM % | -88.6% | -38.1% | -67.0% | 4.1% |
| Other income | 0.34 Cr | 0.01 Cr | 0.0067 Cr | 0.0043 Cr |
| Interest | 2 Cr | 2 Cr | 2 Cr | 2 Cr |
| Depreciation | 2 Cr | 2 Cr | 2 Cr | 2 Cr |
| Profit before tax | -8 Cr | -5 Cr | -6 Cr | -3 Cr |
| Tax % | -0.2% | 0.0% | 0.0% | 0.0% |
| Net profit | -8 Cr | -5 Cr | -6 Cr | -3 Cr |
| EPS (₹) | ₹-3.83 | ₹-2.47 | ₹-2.85 | ₹-1.45 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 43 Cr | Sign in for TTM |
| Operating expenses (approx.) | 58 Cr | Sign in for TTM |
| EBITDA | -15 Cr | Sign in for TTM |
| OPM % | -34.7% | Sign in for TTM |
| Other income | 0.71 Cr | Sign in for TTM |
| Interest | 6 Cr | Sign in for TTM |
| Depreciation | 7 Cr | Sign in for TTM |
| Profit before tax | -27 Cr | Sign in for TTM |
| Tax % | -0.1% | Sign in for TTM |
| Net profit | -27 Cr | Sign in for TTM |
| EPS (₹) | ₹-12.49 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 22 Cr |
| Reserves | -168 Cr |
| Borrowings | 212 Cr |
| Other liabilities | 103 Cr |
| Total liabilities | 169 Cr |
| Fixed assets (net) | 145 Cr |
| CWIP | 1 Cr |
| Investments | 0 Cr |
| Loans & advances | 0.20 Cr |
| Inventories | 6 Cr |
| Trade receivables | 0.05 Cr |
| Cash & bank | 0.14 Cr |
| Other assets | 16 Cr |
| Total assets | 169 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -8 Cr |
| Cash from investing | -5 Cr |
| Cash from financing | 13 Cr |
| Net cash flow | 0.0042 Cr |
| Free cash flow (OCF − Capex) | -13 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -32.9% |
| ROE % | — |
| Debtor days | 0 |
| Inventory days | 881 |
| Days payable | 2651 |
| Cash conversion cycle | -1769 |
| Debt / equity | -0.01 |
| Current ratio | 0.10 |
| Net debt / EBITDA | — |
Compare with peers
Loading peers…